BamSEC and AlphaSense Join Forces
Learn More

Revolution Medicines Inc

NASDAQ: RVMD    
Share price (8/22/25): $37.01    
Market cap (8/22/25): $6.918 billion
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.1
from 10-Q 59 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type That the Company Treats as Private or Confidential. Revenue Participation Right Purchase and Sale Agreement by and Between Revolution Medicines, Inc. and Royalty Pharma Investments 2019 Icav Dated as of June 23, 2025
12/34/56
EX-10.1
from 10-Q 7 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, March 27, 2025
12/34/56
EX-10.2J
from 10-K 25 pages This Sublease (This “Sublease”) Is Entered Into as of November 5, 2024 (The “Effective Date”), by and Between Revolution Medicines, Inc., a Delaware Corporation (“Sublandlord”), and Editco Bio Inc., a Delaware Corporation (“Subtenant”). Sublandlord and Subtenant May Each Be Referred to Herein as a “Party”, and Collectively, the “Parties”
12/34/56
EX-10.2I
from 10-K 27 pages Seventh Amendment to Lease
12/34/56
EX-10.3
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 20 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 25 pages Sixth Amendment to Lease
12/34/56
EX-10.3
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 20 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 25 pages Sixth Amendment to Lease
12/34/56
EX-10.1
from 10-Q 6 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, March 21, 2024
12/34/56
EX-10.3
from 10-Q 5 pages Fifth Amendment to Lease
12/34/56
EX-10.2
from 8-K 8 pages Form of Stockholder Lock-Up Agreement July 31, 2023
12/34/56
EX-10.1
from 8-K 14 pages Form of Company Stockholder Voting Agreement
12/34/56
EX-10
from 10-Q 15 pages Fourth Amendment to Lease
12/34/56
EX-10
from 10-Q 6 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, March 23, 2023
12/34/56
EX-10.1
from 8-K 3 pages First Amendment to Employment Agreement
12/34/56
EX-10.3
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.2
from 10-Q 21 pages Revolution Medicines, Inc. Employment Agreement
12/34/56
EX-10.1
from 10-Q 5 pages Revolution Medicines, Inc. Non-Employee Director Compensation Program as Amended, March 10, 2022
12/34/56